

**AMENDMENTS TO THE CLAIMS**

1. (Canceled)
2. (Currently amended) A-An isolated tumor antigen peptide that is a partial peptide of a protein consisting of the amino acid sequence of SEQ ID NO: 2, wherein the peptide comprises an amino acid sequence of any one of SEQ ID NOS: 3 to 52 and that binds to an HLA antigen and is recognized by cytotoxic T lymphocytes.
3. (Original) The tumor antigen peptide of claim 2 wherein the HLA antigen is HLA-A24 or HLA-A2.
4. (Canceled)
5. (Currently amended) The tumor antigen peptide of claim 4-claim 3 which comprises an amino acid sequence shown in any one of SEQ ID NOs: 3-9 and 25-29.
6. (Currently amended) A derivative of the tumor antigen peptide of claim 4 claim 2, in which the amino acid residue at position 2 and/or the C terminus in the amino acid sequence shown in any one of SEQ ID NOs: 3-52 is substituted by another amino acid residuethe amino acid residue at position 2 in the amino acid sequence shown in any one of SEQ ID NOs: 3-24 is substituted by tyrosine, phenylalanine, methionine, or tryptophan, and/or the amino acid residue at the C-terminus is substituted by phenylalanine, leucine, isoleucine, tryptophan, or methionine, and in which the derivative that binds to an HLA antigen and is recognized by cytotoxic T lymphocytes.

7. (Currently amended) A derivative of the tumor antigen peptide of claim 5, ~~in which the amino acid residue at position 2 and/or the C terminus in the amino acid sequence shown in any one of SEQ ID NOS: 3-9 and 25-29 is substituted by another amino acid residue, and in which the derivative that comprises an amino acid sequence of any one of SEQ ID NOS: 53-64 and that binds to an HLA antigen and is recognized by cytotoxic T lymphocytes.~~

8. (Canceled)

9. (Withdrawn, currently amended) ~~The derivative of claim 6 A derivative of the tumor antigen peptide of claim 2, in which the amino acid residue at position 2 in the amino acid sequence shown in any one of SEQ ID NOS: 25-52 is substituted by leucine, methionine, valine, isoleucine, or glutamine, and/or the amino acid residue at the C-terminus is substituted by valine or leucine, that binds to an HLA antigen and is recognized by cytotoxic T lymphocytes.~~

10. (Canceled)

11. (Currently amended) A pharmaceutical composition for treating tumors, which comprises as an active ingredient at least one of substances selected from the tumor antigen peptides and the derivatives according to any one of claims ~~2 to 10~~ 2, 5-7 and 9, and a pharmaceutically acceptable carrier.

12. (Currently amended) A recombinant polypeptide ~~obtainable produced~~ by expressing the a recombinant DNA comprising at least one of DNAs ~~polynucleotide that encode encodes~~ the tumor antigen peptides or the derivatives peptide or derivative according to any one of claims 2, 3, 5-7 and 9 to 10.

13. (Currently amended) A pharmaceutical composition for treating tumors a tumor, which comprises as an active ingredient the recombinant polypeptide of claim 12, in an amount effective for treating said tumor and a pharmaceutically acceptable carrier.

14. (Currently amended) A diagnostic agent for tumors, which comprises the tumor antigen peptide or the derivative according to any one of claims 2, 3, 5-7 and 9-to-10.

15. (Original) A diagnostic agent for tumors, which comprises the recombinant polypeptide of claim 12.